NGNE profile · all as-reported value updates
Neurogene Inc. (NGNE) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Stockholders' equity | 2022 | 94,331,000 | -145,739,000 | -240,070,000 | -164.73% | revised comparative figure | 0001628280-23-008602 0001404644-25-000012 | 3 filed observations examined for this concept and period. |
| Stockholders' equity | 2021 | 142,864,000 | -91,875,000 | -234,739,000 | -164.31% | revised comparative figure | 0001628280-22-004491 0001404644-24-000020 | 3 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2022 | 37,887,000 | 82,021,000 | 44,134,000 | +53.81% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |
| Liabilities | 2022 | 21,617,000 | 10,638,000 | -10,979,000 | -50.79% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |
| Capital expenditures | 2022 | 1,110,000 | 2,230,000 | 1,120,000 | +50.22% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |
| Operating cash flow | 2022 | -45,607,000 | -52,824,000 | -7,217,000 | -13.66% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |
| Assets | 2022 | 115,948,000 | 109,265,000 | -6,683,000 | -5.76% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |
| Operating income | 2022 | -59,097,000 | -56,517,000 | 2,580,000 | +4.37% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |
| Net income | 2022 | -57,557,000 | -55,189,000 | 2,368,000 | +4.11% | revised comparative figure | 0001628280-23-008602 0001404644-24-000020 | 2 filed observations examined for this concept and period. |